These studies have led to the development of several clinically approved GLP1 receptor agonists that are highly efficacious in the treatment of type 2 diabetes (T2D) and obesity (9, 10). This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.